Diabetic Retinopathy - A Drug Pipeline Analysis Report by Technavio

September 24, 2018

LONDON--(BUSINESS WIRE)--Sep 24, 2018--Technavio has announced their latest drug pipeline analysis report on . The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of diabetic retinopathy. The report also includes a study of the pipeline molecules in various stages including, on-going clinical trials, discovery, and pre-clinical.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005918/en/

Technavio has published a new report on the drug development pipeline for the treatment of diabetic retinopathy, including a detailed study of the pipeline molecules.

Diabetic retinopathy: An overview

Diabetic retinopathy (DR) is a disease that occurs in diabetic patients. It damages the retina, which is light sensitive by nature. It is a serious threatening disease that can cause sight blindness if left untreated. Diabetes damages blood vessels present in the retina. Diabetic retinopathy occurs when blood vessels leak blood and other fluids. This causes swelling of the retinal tissue, resulting in blurred vision. The chances of occurrence of diabetic retinopathy are more in patients who are diabetic for a long time. There are two types of diabetic retinopathy namely non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.

DR is the most common diabetic eye disease, and it is a leading cause of blindness among adults in the US. As per CDC, in 2012, most of the US population with DR were whites, which comprised to 68%. The Hispanic population in the US comprised 16% of the cases and the blacks accounted for 11%.

This report is available at a USD 1,000 discount for a limited time only:

Diabetic retinopathy: Segmentation of pipeline molecules

Technavio’s research segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality, and the targets for the drugs under development. In the current drug pipeline, the most preferred RoA remains through the intravitreal mode, with more than 21% of the pipeline molecules administered through this mode.

Between companies and institutions, companies led the drug development space for the treatment of diabetic retinopathy. Some of the key players include EyeGene, Charlesson, and AptaBio.

Looking for more information?

Some of the key topics covered in the report include:

1. Scope of the Report

2. Regulatory Framework

3. Drug Development Landscape

Drugs under development

4. Drug Development Strategies

Therapies employed Route of administration Therapeutic modality Mechanism of action

5. Recruitment Strategies

Geographical coverage Recruitment status Gender Age

6. Key Companies

Type of players Company overview

7. Discontinued and Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005918/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200




SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 09/24/2018 03:27 PM/DISC: 09/24/2018 03:27 PM


Update hourly